Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Nov;45(11):3084-91.
doi: 10.1128/AAC.45.11.3084-3091.2001.

Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures

Affiliations

Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures

L C McDonald et al. Antimicrob Agents Chemother. 2001 Nov.

Abstract

A survey of 1,203 Escherichia coli isolates from 44 hospitals in Taiwan revealed that 136 (11.3%) isolates were resistant to fluoroquinolones and that another 261 (21.7%) isolates had reduced susceptibility. Resistance was more common in isolates responsible for hospital-acquired (mostly in intensive care units) infections (17.5%) than in other adult inpatient (11.4%; P = 0.08) and outpatient isolates (11.9%; P > 0.1). Similarly, reduced susceptibility was more common in isolates responsible for hospital-acquired infections (30.9%) than in other adult inpatient (21.0%; P = 0.04) and outpatient (21.4%; P = 0.06) isolates. Isolates from pediatric patients were less likely to be resistant (1.3 versus 12.0%; P < 0.01) but were nearly as likely to have reduced susceptibility (17.7 versus 21.9%; P > 0.1) as nonpediatric isolates. There was an inverse relationship in the proportion of isolates that were resistant versus the proportion that had reduced susceptibility among isolates from individual hospitals (R = 0.031; P < 0.05). In an analysis of isolates from two hospitals, all 9 resistant strains possessed double point mutations in gyrA and all 19 strains with reduced susceptibility strains had single point mutations; no mutations were found among fully susceptible strains. Risk factors for resistance included underlying cancer (odds ratio [OR], 83; 95% confidence interval [CI(95)], 7.3 to 2,241; P < 0.001), exposure to a quinolone (OR, undefined; P = 0.02), and exposure to a nonquinolone antibiotic (OR, 20; CI(95), 2.2 to 482; P < 0.001); underlying cancer was the only independent risk factor (OR, 83; CI(95), 8.6 to 807; P < 0.001). There were no significant associations between any of these factors and reduced susceptibility. Whereas acute and chronic quinolone use in cancer patients is a major selective pressure for resistance, other undetermined but distinct selective pressures appear to be more responsible for reduced susceptibility to fluoroquinolones in E. coli.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Distribution of ciprofloxacin inhibition zone diameters for 1,203 E. coli isolates collected throughout Taiwan.
FIG. 2
FIG. 2
Proportion of E. coli isolates with reduced susceptibility to ciprofloxacin versus proportion of E. coli isolates resistant to ciprofloxacin from 40 hospitals that submitted more than 10 isolates.

Similar articles

Cited by

References

    1. Anonymous. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance Report, data summary from January 1996 through December 1997: a report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control. 1999;27:279–284. - PubMed
    1. Blazquez R, Menasalvas A, Carpena I, Ramirez C, Guerrero C, Moreno S. Invasive disease caused by ciprofloxacin-resistant uropathogenic Escherichia coli. Eur J Clin Microbiol Infect Dis. 1999;18:503–505. - PubMed
    1. Canawati H N, el Farra R, Seymour J, Shimashita J, Dunn D, Montgomerie J Z. Ciprofloxacin-resistant Escherichia coli emerging in a rehabilitation medical center. Diagn Microbiol Infect Dis. 1997;29:133–138. - PubMed
    1. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995;20:557–560. - PubMed
    1. Conrad S, Oethinger M, Kaifel K, Klotz G, Marre R, Kern W V. gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli. J Antimicrob Chemother. 1996;38:443–455. - PubMed

MeSH terms